TY - JOUR
T1 - Unveiling Human Proteome Signatures of Heart Failure with Preserved Ejection Fraction
AU - Sebastião, Maria J.
AU - Almeida, Henrique V.
AU - Serra, Margarida
AU - Hamdani, Nazha
AU - Saraiva, Francisca
AU - Lourenço, André P.
AU - Barros, António S.
AU - Vasques-Nóvoa, Francisco
AU - Leite-Moreira, Adelino
AU - Alves, Paula M.
AU - Falcão-Pires, Inês
AU - Gomes-Alves, Patrícia
N1 - Funding Information:
This research was funded by project BRAV3 (H2020, 874827), Fundação para a Ciência e Tecnologia projects: NETDIAMOND-SAICTPAC/0047/2015, iNOVA4Health (UIDB/04462/2020, UIDP/04462/2020), (UIDB/00051/2020), (UIDP/00051/2020), and LS4FUTURE Associated Laboratory (LA/P/0087/2020).
Publisher Copyright:
© 2022 by the authors.
PY - 2022/11
Y1 - 2022/11
N2 - Heart failure with preserved ejection fraction (HFpEF) is a highly prevalent but still poorly understood clinical entity. Its current pathophysiological understanding supports a critical role of comorbidities and their chronic effect on cardiac function and structure. Importantly, despite the replication of some HFpEF phenotypic features, to this day, experimental models have failed to bring new effective therapies to the clinical setting. Thus, the direct investigation of HFpEF human myocardial samples may unveil key, and possibly human-specific, pathophysiological mechanisms. This study employed quantitative proteomic analysis by advanced mass spectrometry (SWATH–MS) to investigate signaling pathways and pathophysiological mechanisms in HFpEF. Protein-expression profiles were analyzed in human left ventricular myocardial samples of HFpEF patients and compared with a mixed control group. Functional analysis revealed several proteins that correlate with HFpEF, including those associated with mitochondrial dysfunction, oxidative stress, and inflammation. Despite the known disease heterogeneity, proteomic profiles could indicate a reduced mitochondrial oxidative phosphorylation and fatty-acid oxidation capacity in HFpEF patients with diabetes. The proteomic characterization described in this work provides new insights. Furthermore, it fosters further questions related to HFpEF cellular pathophysiology, paving the way for additional studies focused on developing novel therapies and diagnosis strategies for HFpEF patients.
AB - Heart failure with preserved ejection fraction (HFpEF) is a highly prevalent but still poorly understood clinical entity. Its current pathophysiological understanding supports a critical role of comorbidities and their chronic effect on cardiac function and structure. Importantly, despite the replication of some HFpEF phenotypic features, to this day, experimental models have failed to bring new effective therapies to the clinical setting. Thus, the direct investigation of HFpEF human myocardial samples may unveil key, and possibly human-specific, pathophysiological mechanisms. This study employed quantitative proteomic analysis by advanced mass spectrometry (SWATH–MS) to investigate signaling pathways and pathophysiological mechanisms in HFpEF. Protein-expression profiles were analyzed in human left ventricular myocardial samples of HFpEF patients and compared with a mixed control group. Functional analysis revealed several proteins that correlate with HFpEF, including those associated with mitochondrial dysfunction, oxidative stress, and inflammation. Despite the known disease heterogeneity, proteomic profiles could indicate a reduced mitochondrial oxidative phosphorylation and fatty-acid oxidation capacity in HFpEF patients with diabetes. The proteomic characterization described in this work provides new insights. Furthermore, it fosters further questions related to HFpEF cellular pathophysiology, paving the way for additional studies focused on developing novel therapies and diagnosis strategies for HFpEF patients.
KW - diabetes mellitus
KW - heart failure with preserved ejection fraction
KW - human cardiac tissue
KW - SWATH–MS proteomics
UR - http://www.scopus.com/inward/record.url?scp=85149892019&partnerID=8YFLogxK
U2 - 10.3390/biomedicines10112943
DO - 10.3390/biomedicines10112943
M3 - Article
AN - SCOPUS:85149892019
SN - 2227-9059
VL - 10
JO - Biomedicines
JF - Biomedicines
IS - 11
M1 - 2943
ER -